PMID- 34871388
OWN - NLM
STAT- MEDLINE
DCOM- 20221004
LR  - 20221021
IS  - 1536-4844 (Electronic)
IS  - 1078-0998 (Print)
IS  - 1078-0998 (Linking)
VI  - 28
IP  - 10
DP  - 2022 Oct 3
TI  - Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and 
      Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
PG  - 1497-1505
LID - 10.1093/ibd/izab302 [doi]
LID - izab302
AB  - BACKGROUND: Severe acute respiratory syndrome coronavirus 2 vaccination is 
      recommended for all individuals with inflammatory bowel disease (IBD), including 
      those on immunosuppressive therapies; however, little is known about vaccine 
      safety and efficacy in these patients or the impact of vaccination on IBD disease 
      course. METHODS: We evaluated coronavirus disease 2019 (COVID-19) vaccine-related 
      adverse events (AEs) and the effect of vaccination on IBD disease course among 
      participants in the PREVENT-COVID (Partnership to Report Effectiveness of 
      Vaccination in populations Excluded from iNitial Trials of COVID) study, a 
      prospective, observational cohort study. Localized and systemic reactions were 
      assessed via questionnaire. Disease flare was defined by worsening IBD symptoms 
      and change in IBD medications. Outcomes were stratified by vaccine type and IBD 
      medication classes. RESULTS: A total of 3316 individuals with IBD received at 
      least 1 COVID-19 vaccine. Injection site tenderness (68%) and fatigue (46% dose 
      1, 68% dose 2) were the most commonly reported localized and systemic AEs after 
      vaccination. Severe localized and systemic vaccine-related AEs were rare. The 
      mRNA-1273 vaccine was associated with significantly greater severe AEs at dose 2 
      (localized 4% vs 2%, systemic 15% vs 10%; P < .001 for both). Prior COVID-19 
      infection, female sex, and vaccine type were associated with severe systemic 
      reactions to dose 1, while age <50 years, female sex, vaccine type, and antitumor 
      necrosis factor and vedolizumab use were associated with severe systemic 
      reactions to dose 2. Overall rates (2%) of IBD flare were low following 
      vaccination. CONCLUSIONS: Our findings provide reassurance that the severe acute 
      respiratory syndrome coronavirus 2 vaccine is safe and well tolerated among 
      individuals with IBD, which may help to combat vaccine hesitancy and increase 
      vaccine confidence.
CI  - (c) 2021 Crohn's & Colitis Foundation. Published by Oxford University Press. All 
      rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
FAU - Weaver, Kimberly N
AU  - Weaver KN
AUID- ORCID: 0000-0002-7407-370X
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, University 
      of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
FAU - Zhang, Xian
AU  - Zhang X
AD  - Division of Pediatric Gastroenterology, Department of Pediatrics, University of 
      North Carolina at Chapel Hill, Chapel Hill, NC, USA.
FAU - Dai, Xiangfeng
AU  - Dai X
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, University 
      of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
FAU - Watkins, Runa
AU  - Watkins R
AD  - Division of Pediatric Gastroenterology and Nutrition, University of Maryland 
      School of Medicine, Baltimore, MD, USA.
FAU - Adler, Jeremy
AU  - Adler J
AD  - Susan B. Meister Child Health Evaluation and Research Center and Division of 
      Pediatric Gastroenterology, University of Michigan, Ann Arbor, MI, USA.
FAU - Dubinsky, Marla C
AU  - Dubinsky MC
AUID- ORCID: 0000-0003-4968-5795
AD  - Susan and Leonard Feinstein IBD Center, Department of Pediatrics, Icahn School of 
      Medicine at Mount Sinai, New York, NY, USA.
FAU - Kastl, Arthur
AU  - Kastl A
AD  - Division of Gastroenterology, Children's Hospital of Philadelphia, Perelman 
      School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
FAU - Bousvaros, Athos
AU  - Bousvaros A
AD  - Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
FAU - Strople, Jennifer A
AU  - Strople JA
AD  - Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, 
      Chicago, IL, USA.
FAU - Cross, Raymond K
AU  - Cross RK
AUID- ORCID: 0000-0001-9766-5196
AD  - Division of Gastroenterology and Hepatology, University of Maryland School of 
      Medicine, Baltimore, MD, USA.
FAU - Higgins, Peter D R
AU  - Higgins PDR
AD  - Division of Gastroenterology & Hepatology, University of Michigan, Ann Arbor, MI, 
      USA.
FAU - Ungaro, Ryan C
AU  - Ungaro RC
AD  - Susan and Leonard Feinstein IBD Center, Department of Medicine, Icahn School of 
      Medicine at Mount Sinai, New York, NY, USA.
FAU - Bewtra, Meenakshi
AU  - Bewtra M
AD  - Division of Gastroenterology, Perelman School of Medicine, University of 
      Pennsylvania, Philadelphia PA, USA.
AD  - Department of Biostatistics and Epidemiology, Perelman School of Medicine, 
      University of Pennsylvania, Philadelphia PA, USA.
FAU - Bellaguarda, Emanuelle
AU  - Bellaguarda E
AD  - Division of Gastroenterology and Hepatology, Northwestern University, Chicago, 
      IL, USAand.
FAU - Farraye, Francis A
AU  - Farraye FA
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
FAU - Boccieri, Margie E
AU  - Boccieri ME
AD  - Division of Pediatric Gastroenterology, Department of Pediatrics, University of 
      North Carolina at Chapel Hill, Chapel Hill, NC, USA.
FAU - Firestine, Ann
AU  - Firestine A
AD  - Division of Pediatric Gastroenterology, Department of Pediatrics, University of 
      North Carolina at Chapel Hill, Chapel Hill, NC, USA.
FAU - Kappelman, Michael D
AU  - Kappelman MD
AD  - Division of Pediatric Gastroenterology, Department of Pediatrics, University of 
      North Carolina at Chapel Hill, Chapel Hill, NC, USA.
AD  - Center for Gastrointestinal Biology and Disease, University of North Carolina at 
      Chapel Hill, Chapel Hill, NC, USA.
FAU - Long, Millie D
AU  - Long MD
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, University 
      of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
AD  - Center for Gastrointestinal Biology and Disease, University of North Carolina at 
      Chapel Hill, Chapel Hill, NC, USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Inflamm Bowel Dis
JT  - Inflammatory bowel diseases
JID - 9508162
RN  - 0 (COVID-19 Vaccines)
RN  - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273)
SB  - IM
CIN - Inflamm Bowel Dis. 2022 Jun 06;:. PMID: 35666245
MH  - 2019-nCoV Vaccine mRNA-1273
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - Female
MH  - Humans
MH  - *Inflammatory Bowel Diseases
MH  - Middle Aged
MH  - Prospective Studies
MH  - SARS-CoV-2
MH  - Vaccination/adverse effects
PMC - PMC8822409
OAB - The severe acute respiratory syndrome coronavirus 2 vaccine is safe and well 
      tolerated among individuals with inflammatory bowel disease (IBD). Severe 
      localized and systemic vaccine-related adverse events were rare, and rates of IBD 
      flare were low (2%) following severe acute respiratory syndrome coronavirus 2 
      vaccination in a cohort of 3316 participants with IBD.
OABL- eng
OTO - NOTNLM
OT  - COVID-19
OT  - Crohn's disease
OT  - preventive care
OT  - ulcerative colitis
OT  - vaccination
EDAT- 2021/12/07 06:00
MHDA- 2022/10/05 06:00
PMCR- 2021/12/06
CRDT- 2021/12/06 17:28
PHST- 2021/09/30 00:00 [received]
PHST- 2021/12/07 06:00 [pubmed]
PHST- 2022/10/05 06:00 [medline]
PHST- 2021/12/06 17:28 [entrez]
PHST- 2021/12/06 00:00 [pmc-release]
AID - 6454297 [pii]
AID - izab302 [pii]
AID - 10.1093/ibd/izab302 [doi]
PST - ppublish
SO  - Inflamm Bowel Dis. 2022 Oct 3;28(10):1497-1505. doi: 10.1093/ibd/izab302.